Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.00 5.11% 123.50 122.00 125.00 127.00 117.50 117.50 134,462 15:51:42
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 70

Reneuron Share Discussion Threads

Showing 7701 to 7722 of 8350 messages
Chat Pages: Latest  310  309  308  307  306  305  304  303  302  301  300  299  Older
DateSubjectAuthorDiscuss
11/11/2019
21:32
Just wanted to get some information about RENEURON as me and a mate brought shares a in 2016 at 1.7p there now at 125p today.. my friend is now saying there as been a reverse stock split and we are still at where we started with them.. does anyone have any information about this or is this false?
hadley 1
30/10/2019
14:31
You could be right....time will tell
scubadiverr
30/10/2019
07:21
Still heading for 50p.Lemmings and mushrooms only.
ken chung
27/10/2019
09:42
Thanks Nobby. The most recent presentation I have seen from RENE on proactive investors is this one: Https://www.youtube.com/watch?v=NsKp92xLzVI Nothing more recent than that so may have missed something or it hasn't been made public in any way yet.
lauders
26/10/2019
11:32
Nobby, thanks for that. I'm not that surprised that the untreated eye seems to improve as you have to factor in the computational stuff between the retina and the "perception" to get the final result. It could be the case that better input to the visual centres/optic tectum is causing changes that benefit the signal processing in both eyes. It's like a mild case of the groundbreaking Colin Blakemore experiment where he demonstrated that, if you raise animals from birth in an environment where they never see a horizontal line, then transfer them to a regular environment, they can't perceive horizontal lines. In this case the signal processing is not used to processing a "sharp" image but, once presented with one, gets better at doing it. It's an idea and, more importantly, good news for both eyes.
small crow
26/10/2019
08:59
Proactive Investors.
nobbygnome
26/10/2019
06:50
Nobby - I must be asleep but what "presenatation last night" please? With RENE it is always good to keep in mind what is said from 4.40 minutes/seconds in during this fairly recent interview: Https://www.youtube.com/watch?v=Gw9icdONjhs
lauders
25/10/2019
18:39
Nobby - thanks for that. Regarding the first cohort being best responders, was there not agreement that a better result would be seen if starting, as they were, from a lower baseline? I think that, and the randomness inherent in such small sample sizes, are more likely causes for differences in the outcomes than cell line drift. I did notice that the first patient, who appears to have regressed in the latest figures, also had a worse result in the untreated eye. So I wondered if it was anything to do with the patient's general health condition as much as the treatment? That led me to wonder whether they weren't missing a trick in the presentation of the figures. It would be useful to have, as well as the difference from same-eye baseline, difference from the untreated eye at the same time. This would capture, admittedly crudely, any change in the patient's condition that affected both eyes, and would also show progress against what might have happened had there been no treatment. It's obviously important to patients to know how they've done against their starting position, but it's also vital that they understand where they are against where they would have been likely to be without treatment. [I hope all that makes sense - it's not easy to express clearly!] Did you discuss any of that with Hunt? When do they expect the next update on the numbers?
supernumerary
25/10/2019
16:47
I was at the presentation last night and questioned Michael Hunt about the 2 patients who lost vision (one is resolving and one is permanent). There is no doubt these adverse events were due to the surgical technique and not the cells. Other similar treatments have had the same problem so it should not be an issue from a regulatory point of view. There was also discussion about the cell line, cell bank etc because the first three patients were the best responders. The question is whether there is some drift in the culture conditions because the cells for each patient come from a fresh vial which have to be expanded. Clearly these cells have to meet certain release criteria but I am not absolutely convinced that there is no issue here with respect to cell line drift. The proof will come as more patients are treated. Another curious result is the fact that the non treated eye also improves to some extent. Clearly they don't really understand the mechanism and that makes me a little suspicious about the result. Again they need more results to prove whether it is real or not. Overall I was reasonably impressed with the presentation.
nobbygnome
25/10/2019
15:11
However, those Woodford shares are now tied up. They are there, but can't be bought or sold until such time as they can be put on the market or a buyer found. In the meantime, news keeps coming out...
masingi
25/10/2019
13:55
I tend to agree with you for once, Mr Chung. Well, I think 50p's probably pushing it a bit but I reckon it'll drop in to double-figures.
jensonbensonjohnson
25/10/2019
13:41
50p coming.Enjoy the drop.Lemmings and mushrooms only.
ken chung
24/10/2019
22:44
Michael Hunt confirmed that Blackrock have the Woodford shareholding, not Park Hill. Shame.
hashertu
24/10/2019
12:39
Patient Capital is to be run by Schroders, and has seen a surge in its share price as a result. It looks as though that fund at least will have some time to recover values. https://www.sharesmagazine.co.uk/news/market/6644395/Schroders-appointed-to-manage-Woodford-Patient-Capital-Trust https://www.cityam.com/schroders-to-take-charge-of-woodford-patient-capital-trust-portfolio/
supernumerary
24/10/2019
12:02
Thanks, big23. That was very helpful to me re the possible timing of any sale. Unfortunately, it isn't very helpful for RENE who must be continuing to burn through their cash. It's a really frustrating situation for the company and us. I think the shares could be flying without this overhang.
dickbush
23/10/2019
14:36
BG23. I suspect that RENE comes under the "unlisted and hard-to-sell listed assets" heading, the sale of which comes the control of Park Hill. Not that that will make much difference to us. Nor the date that dealing will/should start.
hashertu
23/10/2019
10:44
It certainly seems that way.
investordave
23/10/2019
10:16
What news and yet not much share price movement... market doesn't like RENE for sure!!!
stewart_25
23/10/2019
09:55
bg23 If you were looking to acquire wouldn't you want to make a couple of phone calls asap to pick up 33% at a knock-down price from enthusiastic sellers? IMO, if we didn't have the Woodford holding overhanging, with this announcement the company would be getting back to concept status with the share price passing through recent highs.
dickbush
23/10/2019
09:22
exciting news.... but little reaction. still, further confirms my interest and investment in this minnow. re woodford. its likely his/links shareholdings are tied up until January when blackrock come in to liquidate. Sure, sales may be lined up ahead of time, but that in itself is likely to engender a degree of uncertainty amongst interested commercial partners who might be interested in either working with or acquiring an interest in Reneuron.
bg23
23/10/2019
08:24
Despite good news I see the weekly shop sellers are now out again.
investordave
23/10/2019
08:21
This must increase RENE'S attractions either for Fosun-style deals or as an acquisition. Maybe this will stir some institutions to take out Woodford's shares. That's what I want to see.
dickbush
Chat Pages: Latest  310  309  308  307  306  305  304  303  302  301  300  299  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 15:25:56